ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2014
High dose insulin therapy, an evidence based approach to beta blocker/calcium channel blocker toxicity.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Effectiveness of treatments for propranolol toxicity: a systematic review of current approaches and evidence.European journal of clinical pharmacology · 2026Pooled it
- High-dose insulin euglycaemic therapy (HIET): How high is high enough and what are the risks?The Southern African journal of critical care : the official journal of the Critical Care Society · 2026Article
- Massive Amlodipine Overdose Complicated by Multiorgan Failure and Cardiac Arrest: A Case Report.Clinical medicine insights. Case reports · 2025Article
- Treatment of critical aluminum phosphide (rice tablet) poisoning with high-dose insulin: a case report.Journal of medical case reports · 2022Article
- Hopeful News for Physicians Who Involved in the Treatment of Critical Aluminum Phosphide (Rice Pill) Poisoning Patients.Case reports in critical care · 2022Article
- Calcium Channel Blocker Toxicity: A Practical Approach.Journal of multidisciplinary healthcare · 2022Review
- Hyperinsulinemia/euglycemia and intravenous lipid emulsion therapy for the management of severe amlodipine toxicosis in a cat.Clinical case reports · 2021Article
- Human Zinc Phosphide Exposure in Lebanon: A Case Report and Review of the Literature.Clinical practice and cases in emergency medicine · 2021Article
- Article
- Metformin poisoning treated with high dose insulin dextrose therapy: a case series.Acta medica Lituanic · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poison-induced cardiogenic shock (PICS) as a result of beta-blocker (β-blocker) or calcium channel blocker (CCB) overdose is a common and potentially life-threatening condition. Conventional therapies, including fluid resuscitation, atropine, cardiac pacing, calcium, glucagon, and vasopressors often fail to improve hemodynamic status. High-dose insulin (HDI) is an emerging therapeutic modality for PICS. In this article, we discuss the existing literature and highlight the therapeutic success and potential of HDI. Based on the current literature, which is limited primarily to case series and animal models, the authors conclude that HDI can be effective in restoring hemodynamic stability, and recommend considering its use in patients with PICS that is not responsive to traditional therapies. Future studies should be undertaken to determine the optimal dose and duration of therapy for HDI in PICS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.